Commission fines pharmaceutical companies for drug-delay deals
463 views · Published 10 July 2014 · 1:54 · Indexed 23 October 2026
Channel: Rapporteur News · 2014 · News & Politics
The European Commission on Wednesday imposed fines totaling €427.7 million on the French pharmaceutical company Servier and five producers of generic medicines -- Niche/Unichem, Matrix (now part of Mylan), Teva, Krka and Lupin -- for concluding a series of deals of deals all aimed at protecting Servier's bestselling blood pressure medicine, perindopril, from price competition by generics in the EU. Through a technology acquisition and a series of patent settlements with generic rivals, Servier implemented a strategy to exclude competitors and delay the entry of cheaper generic medicine to the detriment of public budgets and patients in breach of EU antitrust rules.
More from this channel
-
2:13
Brussels Minute: EU Wine Reforms disputed
-
2:15
Europe Today: Microsoft's Future at Stake in European Court
-
1:38
EU Week Ahead: Trains, Toys, Sugar, Death Penalty
-
1:26
Europe Today: Barroso in New York for UN climate conference
-
1:58
Strasbourg Minute: Renewable Energy, EU must act
-
3:57
The Exxon Files; FOE targets climate change approach
-
4:47
Animal health strategy proposed for Europe
-
5:50
Europe Today: ELDR Congress in Berlin